The angiotensin receptor antagonist, irbesartan, reduces renal injury in experimental chronic renal failure.

摘要: The effects of chronic treatment with the specific AT1 angiotensin receptor antagonist, irbesartan, or converting enzyme inhibitor, enalapril, were assessed in uninephrectomized fawn-hooded hypertensive rats (FHH) and compared vehicle treatment. Three days after uninephrectomy, irbesartan (240 mg/liter), enalapril (80 mg/liter) administered via drinking water. Systolic blood pressure (SBP) protein excretion rates (UprotV) determined monthly. In receiving (N = 7) 6) SBP (132 +/- 3 mm Hg 133 6, respectively) was essentially normalized at 12 weeks when (169 6 6); all comparisons P < 0.05 by ANOVA). Similarly, proteinuria lower (44 mg/day) (19 2) groups versus (123 10 mg/day). Treatment both drugs associated marked reduction glomerulosclerosis (both 5% vs. vehicle, 43 9%) without effect on glomerular volume. identically prepared rats, capillary hydraulic (PGC, estimated from stop-flow pressure, Psf) FHH (58 1 Hg, N (54 2, than vehicle-treated whom PGC greatly elevated (68 2 Hg; 7). Despite this, GFR single nephron well maintained. These data support a critical role for receptor-mediated, angiotensin-dependent processes pathogenesis hypertension FHH, further implicate as major determinant injury this model.